Cytokines/ Chemokines | Paraneoplastic anti-NMDARE (P, medium, range; pg/ml) | Anti-NMDARE without teratoma (N, medium, range; pg/ml) | Negative symptom control (C, medium, range; pg/ml) | P value | |
---|---|---|---|---|---|
P vs Na | P vs Ca | ||||
TNF-α | 3.19(2.83–3.55) | 3.19(2.32–8.15) | 2.49(1.84–3.55) | 0.613 | 0.039 |
IFN-γ | 47.68(46.03–59.35) | 46.03(30.12–59.35) | 42.77(37.94–57.67) | 0.286 | 0.083 |
CXCL9 | 174(121–336) | 227(121–443) | 227(121–336) | 0.246 | 0.724 |
CXCL10 | 69.03(3.53–147) | 15.6(1.82–7002) | 4.49(2.26–147) | 0.793 | 0.088 |
IL-2 | 415(345–458) | 460(318–630) | 408(327–564) | 0.324 | 0.831 |
IL-4 | 16.17(11.77–31.30) | 26.07(11.77–49.06) | 17.72(8.66–36.3) | 0.099 | 0.914 |
IL-5 | 1.83(1.68–2.25) | 1.97(1.13–4.5) | 1.68(1.41–2.25) | 0.732 | 0.424 |
GM-CSF | 12.56(4.43–18.44) | 5.31(2.77–69.48) | 4(2.02–18.44) | 0.356 | 0.025 |
G-CSF | 26.07(15.37–30.44) | 26.9(15.37–110) | 27.62(18.59–41.01) | 0.429 | 0.52 |
IL-6 | 1.33(0.88–11.33) | 3.26(1.15–68.3) | 1.73(1.15–11.33) | 0.158 | 0.392 |
IL-8 | 50.79(17.89–87.97) | 58.47(11.28–150) | 25.54(3.96–87.97) | 0.694 | 0.055 |
IL-17A | 0.81(−0.81) | 0.81(−5.02) | 0.81(−2.79) | 0.279 | 0.645 |
IL-10 | 6.09(4.89–7.58) | 5.2 (2.16–22.88) | 4.45(2.31–6.48) | 0.393 | 0.033 |
APRIL | 152(56.68–194) | 147(48.19–973) | 74.19(35.96–175) | 0.767 | 0.134 |
BAFF | 157.5(139–266) | 189.5(68.03–1011) | 266(174–314) | 0.491 | 0.055 |
CXCL13 | 27.23(14.07–57.17) | 29.67(11.48–507) | 12.52(10.43–33.96) | 0.818 | 0.055 |
CCL2 | 736.5(656–771) | 788(293–1868) | 852(447–2665) | 0.491 | 0.286 |
CXCL1 | 52(−63.15) | 63.15(23.42–170) | 34.92(−71.33) | 0.155 | 0.668 |
IFN-α | 2.73(1.94–5.86) | 3.19(1.7–8.29) | 2.72(1.94–5.86) | 0.576 | 0.914 |
IL-1α | 43.7(32.68–45.56) | 68.91(39.47–215) | 39.47(34.04–50.27) | 0.026 | 0.522 |
IL-1β | 1.42(0.71–1.83) | 1.42(0.71–2.96) | 1.24(1.05–1.42) | 0.567 | 0.489 |
IL-12 | 124.5(− 133) | 101(− 307) | 56.35(−133) | 0.766 | 0.831 |
VEGF-A | 36.65(26.66–45.66) | 52.68(32.13–119) | 42.65(16.95–52.68) | 0.026 | 0.67 |